Therapy News and Research

RSS

New cancer therapy involves remodelling blood vessels and activating immune cells

Reversing or re-arranging the growth of these vessels in combination with specific immune strategies is a promising new strategy for cancer therapy, says Ruth Ganss, Professor at the Western Australian Institute for Medical Research, Perth, at the 2nd European Congress of Immunology ECI 2009 held in Berlin.

16 Sep 2009

Research study conducted to understand radiation-induced bone loss

A research project looking for ways to reduce bone loss in astronauts may yield methods of improving the bone health of cancer patients undergoing radiation treatment.

16 Sep 2009

PhotoMedex unveils Neova DNA Repair Factor Nourishing Lotion

PhotoMedex, Inc., a leading provider of advanced dermatology, clinical skincare and medical laser products, today announced Neova DNA Repair Factor Nourishing Lotion, the newest addition to its renowned Neova brand of skin and hair products.

16 Sep 2009

Cancer Program established to treat young cancer patients

A new partnership of Providence Health & Services, Childrens Hospital Los Angeles and the Childrens Hospital Los Angeles Medical Group has been developed to treat young adults with cancer, providing diagnostics and treatment for a group that nationwide falls in a gap between adult and pediatric health care.

16 Sep 2009

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

16 Sep 2009

Breast cancer prevention drugs may negatively affect patients

Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from HHS' Agency for Healthcare Research and Quality.

16 Sep 2009

Youthful Aging celebrates 15th anniversary

A most unusual home health care firm is marking its 15th anniversary of helping seniors do more than they think they can do.

16 Sep 2009

Damaged heart tissue is significantly reduced with supersaturated oxygen

Results of a clinical trial published today in Circulation: Cardiovascular Interventions demonstrate that an infusion of blood that is "supersaturated" with oxygen (SS02) can reduce the amount of damaged heart muscle immediately following a life-threatening heart attack

16 Sep 2009

Novartis presents Phase II results of the QVA149 bronchodilator for the treatment of COPD

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announce that Novartis have presented the results of their two Phase II studies evaluating the efficacy, safety and tolerability of QVA149 at the annual congress of the European Respiratory Society (ERS) in Vienna.

16 Sep 2009

Study reveals ineffectiveness of insulin and metformin against inflammatory biomarkers

In patients with recent onset type-2 diabetes, treatment with insulin or the diabetes drug metformin did not reduce inflammatory biomarkers, such as high-sensitivity C-reactive protein, although the treatment did improve glucose control, according to a study in the September 16 issue of JAMA.

16 Sep 2009

Cardiac MRI exams gain prominence in the medical imaging market

Developments in imaging technology and software continue to help cardiac MRI exams gain prominence in the medical imaging market by meeting the demand for faster scan times and the ability to view areas of the body that were previously deemed impossible to image, according to "Medical Imaging Markets: MRI (Magnetic Resonance Imaging) and Ultrasound" by healthcare market research firm Kalorama Information.

16 Sep 2009

Exercise is effective for treating chronic shoulder pain

Supervised exercises are more effective than shockwave treatment to relieve chronic shoulder pain, finds a study published on bmj.com today.

16 Sep 2009

Mobetron portable radiation therapy system for breast cancer treatment

One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the US today. According to a growing body of research, a 60-second course of radiation therapy delivered during surgery dramatically improves results. But, until recently, logistical and administrative difficulties prevented most patients from receiving this crucial treatment until weeks after their procedures.

16 Sep 2009

Findings could lead to new neurological treatments

The power of the imagination is well-known: it's no surprise that scary music is scarier with your eyes closed. But now neuroscientist and psychiatrist Prof. Talma Hendler of Tel Aviv University's Functional Brain Center says that this phenomenon may open the door to a new way of treating people with Alzheimer's, Parkinson's and other neurological diseases.

16 Sep 2009

NCI-funded SPORE grant aims to improve kidney cancer treatment

The National Cancer Institute (NCI) has awarded Beth Israel Deaconess Medical Center (BIDMC) an $11.5 million, five-year SPORE grant to focus on cancers of the kidney. Michael Atkins, MD, Deputy Director of BIDMC's Division of Hematology/Oncology, will oversee the grant, which involves collaborations with Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital via the Dana-Farber/Harvard Cancer Center.

16 Sep 2009

$Heart failure patients with moderate ejection fractions may benefit from CRT$

Heart failure patients with moderate ejection fractions may benefit from CRT

Early findings from a Medtronic, Inc. sponsored study show heart failure patients with moderate ejection fractions, over 35 percent, may receive comparable benefits from cardiac resynchronization therapy (CRT) as compared to those with low ejection fractions of equal to or less than 35 percent.

16 Sep 2009

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

BCLI collaborates with HBI to complete pre-clinical safety experiments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into a strategic agreement with Harlan Biotech Israel Ltd (HBI), a leading Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

15 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009